GeneriCo, LLC Completes Transaction
ST. LOUIS, July 17, 2018 (GLOBE NEWSWIRE) -- GeneriCo, LLC (GeneriCo), a specialty generic drug company, today announced that it completed a deal transaction with a leading US generic pharmaceutical company for the development and commercialization rights for three GeneriCo generic modified release product formulations. Terms of the transaction were not disclosed.
“We are pleased to secure this important transaction that will allow GeneriCo to focus on other modified release generic formulations in the Company’s development portfolio,” said Daniel Thompson, GeneriCo President and CEO. “Such generic products are an important component to therapeutic alternatives and represent a positive step forward to bringing high quality, lower cost medications to the U.S. marketplace.”
About GeneriCo, LLC
GeneriCo, LLC is a generic pharmaceutical company focused on developing and marketing niche, high barrier drugs in the United States. The Company employs a business strategy capitalizing on management’s deep formulation expertise and experience to pursue the development and manufacture of generic drugs.
Contact:
Daniel Thompson, President and CEO
Phone Number: 1.314.330.0800
Email: dan.thompson@genericopharma.com
www.genericopharma.com
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
